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Throughout the past 10 to 15 years, the therapeutic approach to heart failure has undergone 
considerable change. Current treatment not only concerns symptomatic improvement, but 
increasingly focuses on the prevention of disease progression and on reducing mortality. The 
understanding and acceptance of the need to prescribe therapies proven to be effective in large 
controlled trials is vital for the provision of optimal treatment for heart failure patients. 
without beta-blocker administration 
(Wikstrand et al, 2002; Simon et al, 2003). 
The introduction of a beta-blocker should 
therefore be attempted even if the titration 
period is prolonged . 
A major breakthrough has been the 
recommendation for the inclusion of a low 
dose of spironolactone (2Smg) for patients 
with advanced heart failure with systolic 
dysfunction in view of evidence of reduced 
morbidity and mortality (Pitt et al, 1999). 
Whether an aldosterone antagonist is of 
proven benefit in patients with less severe 
disease remains to be fully established. A 
recent study using another aldosterone 
antagonist, eplerenone, has led to this agent 
being recommended for use as adjunct 
treatment in all stages of heart failure follOwing 
myocardial infarction (within 3-14 days of 
event) (Pitt et al, 2003) . The main concern 
with these agents is the potential for 
hyperkalaemia thus necessitating monitoring 
of serum potassium. 
Digoxin is one of the oldest known 
treatments for heart failure. Although it is 
clearly indicated as a rate controller in 
patients with concomitant atrial fibrillation, 
Table 1: Recommended ACE inhibitor 
starting and target doses 
Drug 
enalapril 
lisinopril 
perindopril 
Starting dose 
2.Smgdaily 
2.Smgdaily 
2mgdaily 
Target dose 
1O-20mg twice daily' 
30-3Smg daily' 
4mg daily** 
* doses used in large outcome trials 
** manufacturer's recommendation 
its role in patients with heart failure in sinus 
rhythm is limited. In this latter case, current 
guidelines recommend the use of digoxin 
in patients who remain symptomatic despite 
optimal doses of ACE inhibitors, beta 
blockers, diuretics and spironolactone. 
Digoxin has no effect on reducing mortality 
but may decrease hospitalizations in these 
patients. 
There is no specific role for direct-acting 
vasodilator agents. In case of intolerance to 
ACE inhibitors and angiotensin II receptor 
blockers, the combination of hydralazine 
and nitrates can be considered (Taylor et 
al,2004). 
A summary of the choice of 
pharmacological therapy in the various 
stages of heart failure is shown in table 2 
(The Task Force for the Diagnosis and 
Treatment of Chronic Heart Failure of the 
European Society of Cardiology, 2005). 
Despite longstanding evidence, European 
surveys on drug therapy of heart failure 
patients in primary care and in hospital 
have shown that ACE inhibitors, beta-
blockers, and in particular their 
combination, are not used optimally 
(Cleland et ai, 2002; Cleland et ai, 2003). 
Evidence-based guidelines are now available 
and should be utilized so as to improve 
outcomes for heart failure patients (The 
Task Force for the Diagnosis and Treatment 
of Chronic Heart Failure of the European 
Society of Cardiology, 2005; Hunt et al, 
2001; National Collaborating Centre for 
Chronic Conditions, 2003). 8] 
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Table 2: Heart failure - choice of pharmacological therapy in left ventricular systolic 
dysfunction 
ACE inhibitor Angiotensin Diuretic Beta-blocker Aldosterone Cardiac glyroside 
m(;()2tor blo(;ker antagoni/;t 
Asymptomatic Indicated If ACE intolerant Not indicated PostMI Recent MI With atrial 
left ventricular fibrillation 
dysfunction 
Symptomatic HF Indicated Indicated with or Indicated if fluid Indicated Recent MI (a) when atrial 
(NYHAII) without ACE retention fibrillation 
inhibitor (b) when 
improved from 
morc severe HF 
in sinus rhythm 
Worsening HF Indicated Indicated with or Indicated, Indicated Indicated Indicated 
(NYHAIII-IV) without ACE combination of (under 
inhibitor diuretics pecialist care) 
End-stage Indicated Indicated with or Indicated, Indicated Indicated Indicated 
HF (NYHAIV) without ACE combination of (under 
inhibitor diuretics specialist care) 
NYHA-New York Heart ASSOCiation. HF-heart failure, MI-myocardial infarction 
